Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|The Lancet Oncology|2011Cited by 4.1k
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional RegistryWenhua Liang, Jianxing He, Jiaxi He et al.|Journal of Clinical Oncology|2017Cited by 358
International expert consensus on the management of bleeding during VATS lung surgeryLunxu Liu, Alessandro Brunelli, Yunchao Huang et al.|Annals of Translational Medicine|2019Cited by 42
Iconographies supplémentaires de l'article : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|Unknown|2011Cited by 5